Related Experiment Video
Updated: Apr 5, 2026
A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus
Published on: February 27, 2018
Efficacy of Pseudoephedrine and Oxymetazoline in Preventing Otic Barotrauma: A Systematic Review and Meta-Analysis
Muhnnad A AlGhamdi1,2, Renad Iyad Katib1,2, Razan Osama Bawazir1,2
1College of Medicine, King Saud bin Abdulaziz University for Health Sciences.
Background:
Otic barotrauma (aerotitis media) occurs when the middle-ear pressure fails to equalize during environmental pressure changes (eg, flying, diving, hyperbaric therapy). Oral pseudoephedrine and intranasal oxymetazoline are commonly used prophylactically, but comparative efficacy and the strength of evidence remain uncertain.
Methods:
We registered a protocol on PROSPERO (CRD420251089756) and conducted a PRISMA-guided systematic review of randomized controlled trials evaluating oral pseudoephedrine or intranasal oxymetazoline for the prevention of otic barotrauma in adults. RevMan 5.4 was used for meta-analysis. Relative risks (RR) with 95% CI were pooled using a fixed-effect generic inverse-variance model.
Results:
Four double-blind randomized trials (n=490; conducted 1992-1998) met inclusion. Pseudoephedrine (3 trials) significantly reduced the risk of otic barotrauma versus placebo (RR: 0.55; 95% CI: 0.48-0.66; P <0.00001; I ²=1%), and produced consistent reductions in ear pain (RR: 0.51), blockage (RR: 0.50), and hearing loss (RR: 0.49). Oxymetazoline (2 trials) showed a modest overall effect (RR: 0.75; 95% CI: 0.57-0.99; P =0.05) but inconsistent benefits across individual symptom subgroups and moderate heterogeneity ( I ²=53%). Safety profiles were acceptable in the small trials, although sample sizes were underpowered to detect rare harms.
Conclusions:
In adults, oral pseudoephedrine demonstrated a consistent and clinically meaningful reduction in otic barotrauma in older RCTs; intranasal oxymetazoline showed only modest and variable benefit. The evidence base is dated (1992 to 1998) and limited in size-contemporary, adequately powered RCTs with standardized outcome measures are needed. Clinicians may prefer pseudoephedrine for short-term prophylaxis in adults without contraindications, alongside non-pharmacologic measures.
More Related Videos
Related Concept Videos
01:27Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:30Epistaxis
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Ophthalmic Drug Delivery Systems
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...